Novartis has signed a collaboration and licence agreement with the Drugs for Neglected Diseases initiative (DNDi) for the joint development of LXE408 as a new oral drug for the treatment of visceral leishmaniasis.
Roche Group’s member Genentech has signed a novel immuno-oncology therapies deal with biotechnology firm Bicycle Therapeutics.
British drugmaker GlaxoSmithKline (GSK) has collaborated with Chinese firm Clover Biopharmaceuticals to assess coronavirus (COVID-19) vaccine candidate with the pandemic adjuvant system.
Genetron Holding, a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma to provide clinical trial genomic testing and companion diagnostics development services for InnoCare’s biomarker-driven oncology drug development.
British drugmaker GlaxoSmithKline (GSK) has entered into a deal with Immatics Biotechnologies for the development of novel adoptive cell therapies for multiple cancer indications.
Humanetics announced that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets related to the manufacture of the active pharmaceutical ingredient (API) in BIO 300, a clinical stage drug being developed by Humanetics for oncology and biodefense applications.
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing.
Ligand Pharmaceuticals announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash. Icagen will also be entitled to receive up to an additional $25 million of cash payments based on certain revenue achievements.
Valeritas Holdings announced an agreement to sell substantially all of the business to Zealand Pharma, a Denmark-based biotechnology company.
Roche’s investigational medicine gantenerumab has failed to achieve its primary endpoint in the Phase II/III Alzheimer’s disease (AD) trial.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.